Takeda IR Call

from the beginning

Takeda IR Call

@

• Takeda to acquire late-stage, potential best-in-class, oral allosteric TYK2 inhibitor NDI-034858 from Nimbus Therapeutics

• NDI-034858, a selective allosteric tyrosine kinase 2 (TYK2) inhibitor

• Potential best-in-class efficacy & safety in multiple immune-mediated diseases

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

@